Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2028 for the global life science industry.
London, Boston & Tokyo
- Tweets 7,563
- Following 701
- Followers 6,993
- Likes 620
Want to stay on top of the key trends and insights in biopharma in 2026? Sign up for our monthly Evaluate Discovery newsletter to get the latest thought leadership and analysis from our experts: vist.ly/5jxkd
101
Oncology dealmaking is evolving! The mega-merger era is fading, replaced by a targeted M&A approach. In Ep. 02 of Evaluate Spotlight, Ethan Smith and Sofia Petta discuss the implications for pipelines and financing.
▶️ Watch now: vist.ly/5jt45
Made with AI
217
Most AOP processes falter due to siloed planning, reliance on flawed prior-year data, or skipping market briefs. These issues are fixable! Discover effective AOP practices in our report with J+D Forecasting.
Download it here: vist.ly/5jp5p
Made with AI
199
Most AOP plans start in the wrong place. Teams jump to the numbers before agreeing what the year is even for. Our report shows how to fix it: align on strategy first, then build assumptions you can actually test.
Download the report here: vist.ly/5jnei
Made with AI
214
Have you registered for the new Evaluate Discovery newsletter yet? Don't miss out on our most-read content delivered straight to your inbox. Sign up to receive the Evaluate Discovery newsletter now! ✉️✨ vist.ly/5jhcz
208
Over $500bn in prescription drug sales face generic competition by 2032. Which companies are most exposed, and what are they doing about it?
Find out in the Evaluate World Preview 2026: vist.ly/5jh6z
202
On Nov 17, senior pharma leaders gather in London to discuss pipeline-to-patient productivity, market pressures, and what's next for 2026.
🎤 Keynote by Daniel Chancellor 📍 The Clermont, Charing Cross
RSVP: vist.ly/5jdx2
215
Atlas CI is live. 🚀
The AI-powered competitive intelligence agent built for pharma teams, powered by 30 years of proprietary data.
Ask questions, track competitors, monitor catalysts, and export insights directly to slides.
See it in action: vist.ly/5jcwu
2
2
325
Competitive landscapes. Drug profiles. Catalyst timelines. Leadership briefings.
Atlas CI delivers decision-ready competitive intelligence in minutes, powered by biopharma’s highest-quality data.
🔗 vist.ly/5jckt
245
Evaluate Spotlight Ep.02 CNS is now live!
Watch Wen-Yu Huang and Emma Wille on the investment trends, licensing dynamics, and strategic asset selection shaping the CNS space right now.
▶️ Watch now: vist.ly/5j8cw
🔒 Up next: Ep. 03, Immunology — Dropping 5 October
233
Lilly is forecast to hit $137bn in annual drug sales by 2032. Download the Evaluate World Preview 2026 to see who's pulling ahead and why obesity and autoimmune are doing most of the heavy lifting.
Download it here: vist.ly/5j3iu
231
When it comes to AI, confidence isn't the same as correctness. That's especially true in competitive intelligence.
Every Atlas CI output must pass the Clarity Test before it reaches you: Cited, Consistent, Contextual, Consequential
Explore Atlas CI → vist.ly/5i2y7
1
266
Built for decisions, not demos.
Atlas CI is the first agent on the @NorstellaCo Atlas platform, combining 30+ years of curated pharma data to deliver decision-ready intelligence in minutes.
🔗 evaluate.com/solutions/norst…
1
297
If one person can use your forecast model, you don't have a forecast model.
J+D Forecasting's Andrew Ward & Abigail Spedding host a webinar on fixing broken pharma models — common mistakes + the CATS framework.
Oct 7 | 3pm BST/10am ET
vist.ly/5iwuu
1
228
Patent cliffs, pipeline gaps, and China’s growing biotech influence are reshaping pharma M&A. Six companies have spent $120B+ on deals since 2024. See what’s next in the Evaluate World Preview 2026.
Download it here: vist.ly/5iwtx
1
215
If you've ever shopped while hungry, you'll appreciate this analogy.
The WSJ explores why pharma is favoring smaller, more frequent bolt-on acquisitions, featuring Evaluate data and insights on Lilly, Novartis, and Merck.
🔗vist.ly/5it5c
1
219
Without strategic alignment, the Annual Operating Plan (AOP) becomes just a wish list. Teams must first agree on 3-5 key objectives. Check out our report with J+D Forecasting for best practices: vist.ly/5isyu
Made with AI
210
Evaluate helps you navigate market trends—forecasts, competitive positioning, and more—to drive portfolio growth. Norstella connects R&D, market access, and commercialization, trusted by Top 100 pharma and industry experts. Follow @NorstellaCo to see how we complete the puzzle.
1
208
Suzanne Caruso is back on stage today for her second Pharma CI USA roundtable on deploying AI inside the CI function.
🕚 11:50am EDT | Thu, Sept 17
Missed yesterday's? Catch this one, then stop by our stand for a live Atlas CI demo.
📅 Book time: vist.ly/5irvp
218
Suzanne Caruso runs two roundtables at Pharma CI USA on deploying AI inside the CI function:
Wed Sept 16 | 5:15 pm ET
Thu Sept 17 | 11:50 am ET
Stop by our stand for a live Atlas CI demo.
📅 Book time: vist.ly/5inkx
1
205